Lineage Cell Therapeutics Stock Forum

$Lineage Cell Therapeutics(LCTX.US)$
Lineage Cell Therapeutics Q1 2024 GAAP EPS $(0.04), Inline, Sales $1.444M Beat $1.359M Estimate

$Lineage Cell Therapeutics(LCTX.US)$ Opregen® (Rg6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
Lineage Cell Therapeutics Shares Are Trading Are Higher After the Company Announced 24 Month Visual Acuity Results From Patients Enrolled in a Phase 1/2a Clinical Study of RG6501 in Patients With Geographic Atrophy Secondary to Age-related Macular Degen...

$Lineage Cell Therapeutics(LCTX.US)$ 👀

$Lineage Cell Therapeutics(LCTX.US)$ Lineage Announces FDA Clearance Of IND Amendment For OPC1 Cell Transplant For The Treatment Of Spinal Cord Injury

$Lineage Cell Therapeutics(LCTX.US)$ Lineage Cell Therapeutics' RG6501 (OpRegen) Phase 1/2a Results Show Evidence of Rapid Improvement of Outer Retinal Structure in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

$American Virtual(AVCT.US)$, $Antares Pharma(ATRS.US)$, $IVERIC bio(ISEE.US)$, $Cara Therapeutics(CARA.US)$, $Aehr Test Systems(AEHR.US)$, $Skillz(SKLZ.US)$, $Lineage Cell Therapeutics(LCTX.US)$, $CryoLife(CRY.US)$  and $Foghorn Therapeutics(FHTX.US)$

$Lineage Cell Therapeutics(LCTX.US)$ looking good

$Lineage Cell Therapeutics(LCTX.US)$ about to break the high 👀

$Lineage Cell Therapeutics(LCTX.US)$ looking poised for good things to come.. Upward trend
Lineage, Genentech Ink Cell Therapy Licensing Pact For Ocular Diseases
Benzinga Real-time News
·
09:06
Lineage Cell Therapeutics Inc (NYSE:LCTX) has entered into an exclusive worldwide collaboration and license agreement with Roche Holdings AG's (OTC:RHHBY) Genentech to develop and commercialize retinal pigment epithelium (RPE) cell therapy.